Group items tagged

Abbott laboratories received the U.S. Food and Drug Administration (FDA) for its next-generation Influenza A & B2 and Strep A2 molecular assays. These assays are used for the molecular detection and differentiation of influenza A and B virus. Next-generation Influenza A & B2 and Strep A2 molecular assays are currently available on ID NOW platform, which is a rapid isothermal system. It is used for the detection of infectious diseases such as influenza.

Adenovirus diagnostic testing is the most widely used method for determining the presence of adenoviruses in a culture of healthy volunteers and is adapted from the polymerase chain reaction (PCR) method: a procedure by which DNA strands are broken down into smaller pieces, and then are subjected to amplification reactions with adenoviruses. Because adenoviruses do not copy themselves but rather undergo multiple copied copies during viral replication, several different sequences of adenoviruses will be identified by PCRs. If a suitable sequence is detected, it will be amplified and the resulting product isolated. In the case of patients suspected of having adenovirus, the adenovirus diagnostic testing is done by a polymerase chain reaction (PCR) test that can be performed on the patients' blood samples. Adenoviruses that have been identified by PCR will be identified by the confirmation of specific antibodies against the virus. These specific antibodies will react against the viral copies on the strain of adenovirus in the blood samples and will provide an accurate diagnosis. Patients with suspected AD may be asked to undergo EVGI or MBO testing, both of which will confirm the diagnosis. Besides, EVGI will also provide results regarding the presence of a retrovirus in the patients' lymph nodes, and MBO testing will provide conclusive proof that the patients carry the retrovirus. The main factor driving the adenovirus diagnostic testing market is the growth of the treatment monitoring and diagnostic sector. For instance, according to Policynet, in 2018 the global healthcare sector generated a revenue of approximately US$ 1.853 trillion. Additionally, the expansion of the healthcare sectors in the emerging economies is expected to propel the market growth of adenovirus diagnostic testing. Read more @ https://coherentmarketinsights-blog.blogspot.com/2021/03/rapid-growth-on-adenovirus-diagnostic.html